The US Food and Drug Administration (FDA) gave the green light on Wednesday to a new oral weight-loss medication developed by the Indianapolis-based pharmaceutical company Eli Lilly. The starting dose is projected to cost about $149 per month for those paying without insurance, similar to the Wegovy pill. This decision comes as the GLP-1 drug category continues to grow, with new treatments offering improved weight-loss results and, in some cases, reduced costs. Because orforglipron is taken once a day in pill form, it may be easier for patients to stay consistent with treatment. As a result, Foundayo will enter the market roughly three months after Novo Nordisk’s Wegovy pill, intensifying competition between the two companies in the evolving GLP-1 space.

Source: The Guardian April 01, 2026 18:59 UTC